Amgen Inc. Files 8-K on Financials

TL;DR

Amgen filed an 8-K on Feb 4, 2025, detailing its financial results and condition.

AI Summary

Amgen Inc. filed an 8-K on February 4, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the report period and filing date both being February 4, 2025. Amgen Inc. is incorporated in Delaware and is in the biological products industry.

Why It Matters

This 8-K filing provides an update on Amgen's financial performance and condition, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.

Key Players & Entities

• Amgen Inc. (company) — Registrant
• February 4, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 001-37702 (filing_id) — Commission File Number
• 95-3540776 (tax_id) — IRS Employer Identification No.
• One Amgen Center Drive (address) — Principal executive offices
• Thousand Oaks (city) — Principal executive offices
• California (state) — Principal executive offices
• 91320-1799 (zip_code) — Principal executive offices

FAQ

From the Filing

0000318154-25-000005.txt : 20250204 0000318154-25-000005.hdr.sgml : 20250204 20250204160522 ACCESSION NUMBER: 0000318154-25-000005 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250204 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250204 DATE AS OF CHANGE: 20250204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 25588111 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 8-K 1 amgn-20250204.htm 8-K amgn-20250204 0000318154 false 0000318154 2025-02-04 2025-02-04 0000318154 exch:XNGS us-gaap:CommonStockMember 2025-02-04 2025-02-04 0000318154 exch:XNGS amgn:A2.00SeniorNotesDue2026Member 2025-02-04 2025-02-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2025  - Amgen Inc. (Exact name of registrant as specified in its charter)    Delaware   001-37702   95-3540776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) One Amgen Center Drive   Thousand Oaks California 91320-1799 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code ( 805 ) 447-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value AMGN The Nasdaq Global Select Market 2.000% Senior Notes due 2026 AMGN26 The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. Fourth Quarter and Full Year 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On February 4, 2025 , the Company issued a press release announcing its unaudited results of operations for the three months and year ended December 31, 2024, and its unaudited financial position as of December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measur